S&P 500   4,145.19
DOW   32,803.47
QQQ   322.73
What to Expect from the Markets in a Recession
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
Bangladesh seeks China help to repatriate Rohingya refugees
Can Airbnb Still Thrive in a Recession?
Dems push Biden climate, health priorities toward Senate OK
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
S&P 500   4,145.19
DOW   32,803.47
QQQ   322.73
What to Expect from the Markets in a Recession
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
Bangladesh seeks China help to repatriate Rohingya refugees
Can Airbnb Still Thrive in a Recession?
Dems push Biden climate, health priorities toward Senate OK
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
S&P 500   4,145.19
DOW   32,803.47
QQQ   322.73
What to Expect from the Markets in a Recession
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
Bangladesh seeks China help to repatriate Rohingya refugees
Can Airbnb Still Thrive in a Recession?
Dems push Biden climate, health priorities toward Senate OK
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
S&P 500   4,145.19
DOW   32,803.47
QQQ   322.73
What to Expect from the Markets in a Recession
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is This "Military Tech Crisis" About To Spark A $15B Boom For Investors? (Ad)
Bangladesh seeks China help to repatriate Rohingya refugees
Can Airbnb Still Thrive in a Recession?
Dems push Biden climate, health priorities toward Senate OK
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
NASDAQ:TLIS

Talis Biomedical - TLIS Stock Forecast, Price & News

$0.74
+0.01 (+0.68%)
(As of 08/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.73
$0.79
50-Day Range
$0.74
$1.05
52-Week Range
$0.72
$10.40
Volume
7,429 shs
Average Volume
149,858 shs
Market Capitalization
$19.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Talis Biomedical MarketRank™ Forecast

Analyst Rating
Reduce
1.25 Rating Score
Upside/​Downside
693.7% Upside
$5.83 Price Target
Short Interest
Healthy
1.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.72mentions of Talis Biomedical in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.88) to ($2.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

572nd out of 1,293 stocks

Analytical Instruments Industry

18th out of 35 stocks

TLIS stock logo

About Talis Biomedical (NASDAQ:TLIS) Stock

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Receive TLIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter.

TLIS Stock News Headlines

TLIS 2-DAY DEADLINE ALERT: Hagens Berman,...
See More Headlines
Receive TLIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter.

TLIS Company Calendar

Last Earnings
8/02/2022
Today
8/08/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TLIS
Fax
N/A
Employees
242
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.83
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+688.3%
Consensus Rating
Reduce
Rating Score (0-4)
1.25
Research Coverage
4 Analysts

Profitability

Net Income
$-192,040,000.00
Net Margins
-2,629.45%
Pretax Margin
-2,629.45%

Debt

Sales & Book Value

Annual Sales
$8.19 million
Book Value
$8.90 per share

Miscellaneous

Free Float
N/A
Market Cap
$19.70 million
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Mr. Robert Kelley MBA (Age 50)
    CEO & Director
    Comp: $392.41k
  • Dr. Rustem F. Ismagilov Ph.D. (Age 48)
    Co-Founder, Chairman of Scientific Advisory Board & Director
    Comp: $110.44k
  • Mr. J. Roger Moody Jr. (Age 54)
    M.B.A., Chief Financial Officer
    Comp: $448.83k
  • Mr. Liang Li Ph.D.
    Co-Founder and Director of Technology & Strategy
  • Mr. J. Roger Moody (Age 54)
    Chief Financial Officer
  • Ms. Emily Faucette
    Sr. VP of Corp. Communications & Investor Relations
  • Ms. Jill Green
    Sr. VP of Legal
  • Mr. Matthew Pepe
    Sr. Director of Human Resource
  • Ms. Margaret Barrett M.S.
    Controller
  • Gillian Green
    Company Sec.













TLIS Stock - Frequently Asked Questions

Should I buy or sell Talis Biomedical stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Talis Biomedical in the last year. There are currently 3 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" Talis Biomedical stock.
View analyst ratings for Talis Biomedical
or view top-rated stocks.

What is Talis Biomedical's stock price forecast for 2022?

4 brokerages have issued 12 month price targets for Talis Biomedical's shares. Their TLIS stock forecasts range from $1.50 to $9.00. On average, they predict Talis Biomedical's stock price to reach $5.83 in the next twelve months. This suggests a possible upside of 693.7% from the stock's current price.
View analysts' price targets for Talis Biomedical
or view top-rated stocks among Wall Street analysts.

How has Talis Biomedical's stock performed in 2022?

Talis Biomedical's stock was trading at $4.01 on January 1st, 2022. Since then, TLIS shares have decreased by 81.7% and is now trading at $0.7350.
View the best growth stocks for 2022 here
.

When is Talis Biomedical's next earnings date?

Talis Biomedical is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our earnings forecast for Talis Biomedical
.

How were Talis Biomedical's earnings last quarter?

Talis Biomedical Co. (NASDAQ:TLIS) announced its quarterly earnings data on Tuesday, August, 2nd. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by $0.21. Talis Biomedical had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 2,629.45%.

When did Talis Biomedical IPO?

(TLIS) raised $150 million in an IPO on Friday, February 12th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

What is Talis Biomedical's stock symbol?

Talis Biomedical trades on the NASDAQ under the ticker symbol "TLIS."

How do I buy shares of Talis Biomedical?

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Talis Biomedical's stock price today?

One share of TLIS stock can currently be purchased for approximately $0.74.

How much money does Talis Biomedical make?

Talis Biomedical (NASDAQ:TLIS) has a market capitalization of $19.56 million and generates $8.19 million in revenue each year.

How many employees does Talis Biomedical have?

Talis Biomedical employs 242 workers across the globe.

How can I contact Talis Biomedical?

Talis Biomedical's mailing address is 230 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The official website for Talis Biomedical is talis.bio. The company can be reached via phone at 650-433-3000 or via email at ir@talisbio.com.

This page (NASDAQ:TLIS) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.